Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne)
Open Access
- 1 January 2002
- journal article
- letter
- Published by BMJ in British Journal of Ophthalmology
- Vol. 86 (1) , 118-119
- https://doi.org/10.1136/bjo.86.1.118
Abstract
We have recently looked at a cohort of 1418 new referrals (out of a possible 1481 (95.7%)) seen in the 166 consultant outpatient clinics at Southampton Eye Unit, between 1 December 2000 and 31 January 2001. Diagnoses were obtained from the consultant's letter to the referring doctor following the clinic visit to obtain the spectrum of diagnoses made. When two eyes were similarly affected this was recorded as a single diagnostic event.Keywords
This publication has 8 references indexed in Scilit:
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.2001
- Age related macular degenerationBMJ, 2000
- LASER TREATMENTS WITH VERTEPORFIN THERAPY AND ITS POTENTIAL IMPACT ON RETINAL PRACTICESRetina, 2000
- Treatment of age-related macular degenerationClinical Eye and Vision Care, 2000
- A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia, Ocular Histoplasmosis Syndrome, Angioid Streaks, and Idiopathic CausesArchives of Ophthalmology (1950), 2000
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.1999
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999
- Use of Eye Care Services among the 1991 Medicare PopulationOphthalmology, 1996